Haleon Plc - ADR (HLN) | Financial Analysis & Statements
Haleon Plc - ADR Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2024Income Metrics
Revenue
2.8B
Gross Profit
1.5B
55.38%
Operating Income
350.0M
12.69%
Net Income
222.0M
8.05%
Balance Sheet Metrics
Total Assets
32.6B
Total Liabilities
16.1B
Shareholders Equity
16.5B
Debt to Equity
0.98
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2024
Annual Income Flow
2025
Haleon Plc - ADR Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 11.0B | 11.2B | 11.3B | 10.9B | 9.5B |
| Cost of Goods Sold | 4.0B | 4.4B | 4.6B | 4.3B | 3.6B |
| Gross Profit | 7.1B | 6.8B | 6.7B | 6.6B | 6.0B |
| Gross Margin % | 64.2% | 60.7% | 59.7% | 60.6% | 62.3% |
| Operating Expenses | |||||
| Research & Development | 316.0M | 298.0M | 311.0M | 300.0M | 257.0M |
| Selling, General & Administrative | 4.4B | 4.5B | 4.4B | 4.5B | 4.1B |
| Other Operating Expenses | -12.0M | -132.0M | 27.0M | -31.0M | -31.0M |
| Total Operating Expenses | 4.7B | 4.6B | 4.8B | 4.8B | 4.3B |
| Operating Income | 2.4B | 2.2B | 2.0B | 1.8B | 1.6B |
| Operating Margin % | 21.9% | 19.6% | 17.7% | 16.8% | 17.2% |
| Non-Operating Items | |||||
| Interest Income | 57.0M | 65.0M | 25.0M | 62.0M | 13.0M |
| Interest Expense | 347.0M | 394.0M | 414.0M | 278.0M | 16.0M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 2.2B | 1.9B | 1.6B | 1.6B | 1.6B |
| Income Tax | 472.0M | 435.0M | 517.0M | 499.0M | 197.0M |
| Effective Tax Rate % | 21.9% | 22.8% | 31.8% | 30.8% | 12.0% |
| Net Income | 1.7B | 1.5B | 1.1B | 1.1B | 1.4B |
| Net Margin % | 15.2% | 13.1% | 9.8% | 10.3% | 15.1% |
| Key Metrics | |||||
| EBITDA | 2.8B | 2.6B | 2.4B | 2.2B | 1.9B |
| EPS (Basic) | $0.37 | $0.32 | $0.23 | $0.23 | $0.30 |
| EPS (Diluted) | $0.37 | $0.31 | $0.23 | $0.23 | $0.30 |
| Basic Shares Outstanding | 4491000000 | 4563291139 | 3642464618 | 3669203978 | 3669034655 |
| Diluted Shares Outstanding | 4491000000 | 4563291139 | 3642464618 | 3669203978 | 3669034655 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Haleon Plc - ADR Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 1.3B | 2.2B | 994.0M | 606.0M | 347.0M |
| Short-term Investments | - | - | - | - | 1.0M |
| Accounts Receivable | 1.6B | 1.6B | 1.4B | 1.5B | 1.3B |
| Inventory | 1.0B | 1.2B | 1.4B | 1.3B | 951.0M |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 4.6B | 5.7B | 4.8B | 4.1B | 5.3B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.0M | 0 | 1.0M | 0 | 1.0M |
| Goodwill | 33.7B | 34.4B | 35.2B | 36.8B | 35.4B |
| Intangible Assets | 17.5B | 18.0B | 18.5B | 20.0B | 18.9B |
| Long-term Investments | 9.0M | 0 | 65.0M | 44.0M | 12.0M |
| Other Non-Current Assets | 37.0M | 71.0M | 114.0M | 132.0M | 320.0M |
| Total Non-Current Assets | 28.1B | 28.6B | 29.2B | 30.8B | 29.2B |
| Total Assets | 32.6B | 34.3B | 34.1B | 34.8B | 34.5B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.1B | 2.0B | 1.9B | 1.8B | 1.4B |
| Short-term Debt | 836.0M | 1.5B | 656.0M | 437.0M | 904.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | 18.0M |
| Total Current Liabilities | 4.9B | 5.8B | 4.6B | 4.4B | 4.2B |
| Non-Current Liabilities | |||||
| Long-term Debt | 7.7B | 8.6B | 8.8B | 10.0B | 87.0M |
| Deferred Tax Liabilities | 3.2B | 3.4B | 3.5B | 3.6B | 3.4B |
| Other Non-Current Liabilities | 30.0M | 28.0M | 53.0M | 22.0M | 8.0M |
| Total Non-Current Liabilities | 11.2B | 12.3B | 12.7B | 14.0B | 3.7B |
| Total Liabilities | 16.1B | 18.1B | 17.3B | 18.4B | 8.0B |
| Equity | |||||
| Common Stock | 90.0M | 91.0M | 92.0M | 92.0M | 1.0M |
| Retained Earnings | 27.8B | 27.3B | 27.5B | 26.7B | 37.5B |
| Treasury Stock | 156.0M | 116.0M | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 16.5B | 16.2B | 16.7B | 16.5B | 26.5B |
| Key Metrics | |||||
| Total Debt | 8.6B | 10.1B | 9.5B | 10.4B | 991.0M |
| Working Capital | -383.0M | -94.0M | 178.0M | -311.0M | 1.0B |
Balance Sheet Composition
Haleon Plc - ADR Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.7B | 1.5B | 1.1B | 1.1B | 1.4B |
| Depreciation & Amortization | - | - | - | - | 268.0M |
| Stock-Based Compensation | 86.0M | 102.0M | 76.0M | 15.0M | 0 |
| Working Capital Changes | 131.0M | 48.0M | -219.0M | -206.0M | -342.0M |
| Operating Cash Flow | 2.2B | 1.9B | 1.3B | 1.1B | 1.5B |
| Investing Activities | |||||
| Capital Expenditures | -322.0M | -250.0M | -234.0M | -304.0M | -216.0M |
| Acquisitions | 13.0M | 446.0M | -71.0M | 0 | 0 |
| Investment Purchases | -6.0M | 0 | - | - | - |
| Investment Sales | - | 0 | 0 | 700.0M | 100.0M |
| Investing Cash Flow | -315.0M | 196.0M | -305.0M | 396.0M | -116.0M |
| Financing Activities | |||||
| Share Repurchases | -654.0M | -619.0M | - | - | - |
| Dividends Paid | -612.0M | -570.0M | -388.0M | -2.7B | -1.1B |
| Debt Issuance | 46.0M | 1.2B | 0 | 11.0B | 8.0M |
| Debt Repayment | -1.4B | -562.0M | -553.0M | -1.5B | 0 |
| Financing Cash Flow | -2.7B | -1.0B | -1.1B | 7.2B | -1.1B |
| Free Cash Flow | 2.2B | 2.0B | 1.8B | 1.7B | 1.1B |
| Net Change in Cash | -845.0M | 1.1B | -31.0M | 8.7B | 278.0M |
Cash Flow Trend
Haleon Plc - ADR Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
18.72
Forward P/E
15.42
Price to Book
1.88
Price to Sales
3.78
PEG Ratio
15.42
Profitability Ratios
Profit Margin
15.11%
Operating Margin
23.17%
Return on Equity
10.27%
Return on Assets
4.67%
Financial Health
Current Ratio
0.92
Debt to Equity
52.37
Beta
0.33
Per Share Data
EPS (TTM)
$0.50
Book Value per Share
$4.99
Revenue per Share
$2.46
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| HLN | 42.4B | 18.72 | 1.88 | 10.27% | 15.11% | 52.37 |
| Zoetis | 49.8B | 19.58 | 15.04 | 65.99% | 28.24% | 279.59 |
| United Therapeutics | 25.1B | 20.60 | 3.53 | 19.72% | 41.94% | 0.53 |
| Viatris | 17.0B | 235.80 | 1.15 | -21.08% | -24.58% | 99.91 |
| Intra-Cellular | 14.0B | -183.15 | 12.20 | -8.58% | -10.97% | 1.48 |
| Regencell Bioscience | 14.0B | -3,258.62 | 2,929.00 | -54.81% | 0.00% | 11.20 |
Financial data is updated regularly. All figures are in the company's reporting currency.






